BAT1806 vs tocilizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: IL-6 receptor · full Rheumatoid Arthritis pipeline
BAT1806 · Tofidence
Marketed by Organon and partners
NCT03830203 · Phase 3 · completed
The study was randomized, quadruple-blind, and actively controlled with EU-licensed Actemra, enrolling 621 participants; its primary endpoint was the clinical ACR20 response at 6 months. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Percentage of Participants With an American College of Rheumatology 20 Percent (%) (ACR20) Response (6 months): ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins (met)
Result source: NCT03830203
tocilizumab · Actemra / RoActemra
Marketed by Roche and partners
NCT03155347 · Phase 3 · completed
This randomized, double-blind, active-comparator trial of 340 participants met its primary endpoint: about half of tocilizumab-treated patients achieved an ACR20 response at 24 weeks, compared with a quarter on methotrexate alone, a highly statistically significant difference for both the combination and monotherapy arms.
Next expected readout: August 2028 · NCT05869955 (registry estimate)
Reported efficacy
Percentage of Participants With an American College of Rheumatology (ACR) 20 (ACR20) Response at Week 24: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001 (met)
Result source: NCT03155347
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BAT1806 | tocilizumab |
|---|---|---|
| ACR20 | 69.9% vs 67.9%avs reference tocilizumabNCT03830203 | 60.9% vs 31.5%+29.4 vs placeboNCT012325698 other results
|
| ACR50 | —Not posted · NCT03830203 | 38.9% vs 19.8%+19.1 vs placeboNCT001065355 other results
|
| ACR70 | —Not posted · NCT03830203 | 22.4% vs 12.2%+10.2 vs placeboNCT001065355 other results
|
| DAS28-CRP remission | —Not posted · NCT03830203 | —Not posted · NCT00106548 |
| HAQ-DI, change | —Not posted · NCT03830203 | -0.5 vs -0.3−0.2 vs placeboNCT012325696 other results
|
| Modified Sharp score, change | —Not posted · NCT03830203 | 0.4 vs 2.0−1.6 vs placeboNCT001065358 other results
|
ACR20
- BAT1806
- 69.9% vs 67.9%avs reference tocilizumabNCT03830203
- tocilizumab
- 60.9% vs 31.5%+29.4 vs placeboNCT01232569
8 other results
- 56.3% vs 27% NCT00106535
- 50.6% vs 27% NCT00106535
- 55.8% vs 24.7% NCT00106535
- 54.5% vs 29.3% NCT00106535
- 47.9% vs 24.7% NCT00106535
- 49.1% vs 29.3% NCT00106535
- 52.9% vs 25% NCT03155347
- 50% vs 25% NCT03155347
ACR50
- BAT1806
- —Not posted · NCT03830203
- tocilizumab
- 38.9% vs 19.8%+19.1 vs placeboNCT00106535
5 other results
- 36.4% vs 10.2% NCT00106535
- 32.2% vs 9.7% NCT00106535
- 37.6% vs 19.8% NCT00106535
- 30.3% vs 10.2% NCT00106535
- 25.1% vs 9.7% NCT00106535
ACR70
- BAT1806
- —Not posted · NCT03830203
- tocilizumab
- 22.4% vs 12.2%+10.2 vs placeboNCT00106535
5 other results
- 20.1% vs 3.8% NCT00106535
- 12.6% vs 2% NCT00106535
- 24.3% vs 12.2% NCT00106535
- 16.5% vs 3.8% NCT00106535
- 11% vs 2% NCT00106535
DAS28-CRP remission
- BAT1806
- —Not posted · NCT03830203
- tocilizumab
- —Not posted · NCT00106548
HAQ-DI, change
- BAT1806
- —Not posted · NCT03830203
- tocilizumab
- -0.5 vs -0.3−0.2 vs placeboNCT01232569
6 other results
- -0.6 vs -0.5 NCT00106535
- -0.6 vs -0.4 NCT00106535
- -0.5 vs -0.3 NCT00106535
- -0.6 vs -0.5 NCT00106535
- -0.5 vs -0.4 NCT00106535
- -0.5 vs -0.3 NCT00106535
Modified Sharp score, change
- BAT1806
- —Not posted · NCT03830203
- tocilizumab
- 0.4 vs 2.0−1.6 vs placeboNCT00106535
8 other results
- 0.3 vs 1.1 NCT00106535
- 0.6 vs 2.0 NCT00106535
- 0.3 vs 1.1 NCT00106535
- 0.6 vs 1.2 NCT01232569
- 0.3 vs 1.6 NCT00106535
- 0.2 vs 0.5 NCT00106535
- 0.5 vs 1.6 NCT00106535
- 0.2 vs 0.5 NCT00106535
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. BAT1806: 0 of 4 rows · tocilizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | BAT1806 | tocilizumab |
|---|---|---|
| Dropout rate | — | 57.7%Tocilizumaba NCT01941095 · Phase 3 · other show 49 more results—Tocilizumab + Methotrexate or Othe NCT01941095 · Phase 3 · combination —Tocilizumab Monotherapy NCT01941095 · Phase 3 · monotherapy 19.3% NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —8 mg/kg NCT00106535 · Phase 3 · combination 22.7%8 mg/kg NCT00106535 · Phase 3 · combination —4 mg/kg NCT00106535 · Phase 3 · combination 22.9%4 mg/kg NCT00106535 · Phase 3 · combination 10.6%Tocilizumab IV NCT01194414 · Phase 3 —Tocilizumab IV Then Tocilizumab SC NCT01194414 · Phase 3 9.4%Tocilizumab SC NCT01194414 · Phase 3 —Tocilizumab SC Then Tocilizumab IV NCT01194414 · Phase 3 —Tocilizumab Pre-filled Syringe NCT01232569 · Phase 3 —Tocilizumab Pre-filled Syringe to NCT01232569 · Phase 3 3.6% NCT01331837 · Phase 4 11.7%Tocilizumab+Prednisone (Constant D NCT02573012 · Phase 4 · registry result, not featured evidence · combination 11.5%Tocilizumab+Prednisone (Tapering D NCT02573012 · Phase 4 · registry result, not featured evidence · combination 18.5% NCT01717859 · Phase 4 · registry result, not featured evidence 3.8% NCT01715831 · Phase 4 · registry result, not featured evidence 39.3% NCT01149057 · Phase 4 · registry result, not featured evidence —TCZ + MTX (Not Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + MTX (Post-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + MTX (Pre-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence · combination 3.6%TCZ + MTX (Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + Placebo (Post-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence —TCZ + Placebo (Pre-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence 4.9%TCZ + Placebo (Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence 55.9% NCT01219933 · Phase 4 · registry result, not featured evidence 18.3% NCT01163747 · Phase 4 · registry result, not featured evidence · combination —8 mg/kg NCT01195272 · Phase 4 · registry result, not featured evidence 14.7%8 mg/kg NCT01119859 · Phase 4 · registry result, not featured evidence — NCT01089023 · Phase 4 · registry result, not featured evidence —8 mg/kg NCT01034397 · Phase 4 · registry result, not featured evidence 3.5% NCT00996203 · Phase 4 · registry result, not featured evidence — NCT02010216 · Phase 4 · registry result, not featured evidence —8 mg/kg NCT01010503 · Phase 4 · registry result, not featured evidence 14.3% NCT02046616 · Phase 3 · registry result, not featured evidence · combination 68.2%Tocilizumab Monotherapy NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy 53.6%Tocilizumab in Combination With Me NCT02046603 · Phase 3 · registry result, not featured evidence · combination 14.5% NCT01941940 · Phase 3 · registry result, not featured evidence 11.3% NCT01987479 · Phase 3 · registry result, not featured evidence · combination 17.4% NCT01668966 · Phase 3 · registry result, not featured evidence 14.1%Phase 1: Combination Therapy NCT01995201 · Phase 3 · registry result, not featured evidence · combination 13.5%Phase 1: Tocilizumab Monotherapy NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy 16.5%TCZ - All Participants NCT02001987 · Phase 3 · registry result, not featured evidence —TCZ MONO - All Participants NCT02001987 · Phase 3 · registry result, not featured evidence 18.2% NCT01734993 · Phase 3 · registry result, not featured evidence 1.9% NCT01951170 · Phase 3 · registry result, not featured evidence 20% NCT01655381 · Phase 3 · registry result, not featured evidence 15% NCT01988012 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | — | 11.3%Tocilizumaba NCT01941095 · Phase 3 · other show 49 more results—Tocilizumab + Methotrexate or Othe NCT01941095 · Phase 3 · combination —Tocilizumab Monotherapy NCT01941095 · Phase 3 · monotherapy 10.5% NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 —8 mg/kg NCT00106535 · Phase 3 · combination —8 mg/kg NCT00106535 · Phase 3 · combination —4 mg/kg NCT00106535 · Phase 3 · combination —4 mg/kg NCT00106535 · Phase 3 · combination 6.3%Tocilizumab IV NCT01194414 · Phase 3 —Tocilizumab IV Then Tocilizumab SC NCT01194414 · Phase 3 4.4%Tocilizumab SC NCT01194414 · Phase 3 —Tocilizumab SC Then Tocilizumab IV NCT01194414 · Phase 3 —Tocilizumab Pre-filled Syringe NCT01232569 · Phase 3 —Tocilizumab Pre-filled Syringe to NCT01232569 · Phase 3 — NCT01331837 · Phase 4 3.9%Tocilizumab+Prednisone (Constant D NCT02573012 · Phase 4 · registry result, not featured evidence · combination 3.8%Tocilizumab+Prednisone (Tapering D NCT02573012 · Phase 4 · registry result, not featured evidence · combination 9.3% NCT01717859 · Phase 4 · registry result, not featured evidence 3.8% NCT01715831 · Phase 4 · registry result, not featured evidence 9% NCT01149057 · Phase 4 · registry result, not featured evidence —TCZ + MTX (Not Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + MTX (Post-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + MTX (Pre-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence · combination 3.6%TCZ + MTX (Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + Placebo (Post-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence —TCZ + Placebo (Pre-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence 1.2%TCZ + Placebo (Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence 11.8% NCT01219933 · Phase 4 · registry result, not featured evidence 8.3% NCT01163747 · Phase 4 · registry result, not featured evidence · combination —8 mg/kg NCT01195272 · Phase 4 · registry result, not featured evidence 5.5%8 mg/kg NCT01119859 · Phase 4 · registry result, not featured evidence — NCT01089023 · Phase 4 · registry result, not featured evidence —8 mg/kg NCT01034397 · Phase 4 · registry result, not featured evidence 1.5% NCT00996203 · Phase 4 · registry result, not featured evidence — NCT02010216 · Phase 4 · registry result, not featured evidence —8 mg/kg NCT01010503 · Phase 4 · registry result, not featured evidence 9.8% NCT02046616 · Phase 3 · registry result, not featured evidence · combination 0%Tocilizumab Monotherapy NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy 0.7%Tocilizumab in Combination With Me NCT02046603 · Phase 3 · registry result, not featured evidence · combination 4.8% NCT01941940 · Phase 3 · registry result, not featured evidence 4.7% NCT01987479 · Phase 3 · registry result, not featured evidence · combination — NCT01668966 · Phase 3 · registry result, not featured evidence 4.6%Phase 1: Combination Therapy NCT01995201 · Phase 3 · registry result, not featured evidence · combination 5.4%Phase 1: Tocilizumab Monotherapy NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy 6.5%TCZ - All Participants NCT02001987 · Phase 3 · registry result, not featured evidence —TCZ MONO - All Participants NCT02001987 · Phase 3 · registry result, not featured evidence 9.1% NCT01734993 · Phase 3 · registry result, not featured evidence — NCT01951170 · Phase 3 · registry result, not featured evidence — NCT01655381 · Phase 3 · registry result, not featured evidence 5% NCT01988012 · Phase 3 · registry result, not featured evidence |
| Serious AEs | — | —Tocilizumaba NCT01941095 · Phase 3 · other show 49 more results7.6%Tocilizumab + Methotrexate or Othe NCT01941095 · Phase 3 · combination 6.5%Tocilizumab Monotherapy NCT01941095 · Phase 3 · monotherapy 8.8% NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 25.3%8 mg/kg NCT00106535 · Phase 3 · combination —8 mg/kg NCT00106535 · Phase 3 · combination 9.7%4 mg/kg NCT00106535 · Phase 3 · combination —4 mg/kg NCT00106535 · Phase 3 · combination 12.7%Tocilizumab IV NCT01194414 · Phase 3 11.3%Tocilizumab IV Then Tocilizumab SC NCT01194414 · Phase 3 13.9%Tocilizumab SC NCT01194414 · Phase 3 12.5%Tocilizumab SC Then Tocilizumab IV NCT01194414 · Phase 3 8.2%Tocilizumab Pre-filled Syringe NCT01232569 · Phase 3 10.1%Tocilizumab Pre-filled Syringe to NCT01232569 · Phase 3 31.1% NCT01331837 · Phase 4 3.1%Tocilizumab+Prednisone (Constant D NCT02573012 · Phase 4 · registry result, not featured evidence · combination 5.3%Tocilizumab+Prednisone (Tapering D NCT02573012 · Phase 4 · registry result, not featured evidence · combination 1.9% NCT01717859 · Phase 4 · registry result, not featured evidence 15.4% NCT01715831 · Phase 4 · registry result, not featured evidence 24.8% NCT01149057 · Phase 4 · registry result, not featured evidence 11.5%TCZ + MTX (Not Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence · combination 1.2%TCZ + MTX (Post-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence · combination 0%TCZ + MTX (Pre-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence · combination —TCZ + MTX (Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence · combination 4.9%TCZ + Placebo (Post-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence 1.2%TCZ + Placebo (Pre-randomization) NCT01399697 · Phase 4 · registry result, not featured evidence —TCZ + Placebo (Randomized) NCT01399697 · Phase 4 · registry result, not featured evidence — NCT01219933 · Phase 4 · registry result, not featured evidence 5% NCT01163747 · Phase 4 · registry result, not featured evidence · combination 19%8 mg/kg NCT01195272 · Phase 4 · registry result, not featured evidence 11.7%8 mg/kg NCT01119859 · Phase 4 · registry result, not featured evidence 8.4% NCT01089023 · Phase 4 · registry result, not featured evidence 5.7%8 mg/kg NCT01034397 · Phase 4 · registry result, not featured evidence 6% NCT00996203 · Phase 4 · registry result, not featured evidence 0% NCT02010216 · Phase 4 · registry result, not featured evidence 9.4%8 mg/kg NCT01010503 · Phase 4 · registry result, not featured evidence 9% NCT02046616 · Phase 3 · registry result, not featured evidence · combination 14.3%Tocilizumab Monotherapy NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy 5%Tocilizumab in Combination With Me NCT02046603 · Phase 3 · registry result, not featured evidence · combination 7.5% NCT01941940 · Phase 3 · registry result, not featured evidence 9.3% NCT01987479 · Phase 3 · registry result, not featured evidence · combination 9.5% NCT01668966 · Phase 3 · registry result, not featured evidence 3.1%Phase 1: Combination Therapy NCT01995201 · Phase 3 · registry result, not featured evidence · combination 4.1%Phase 1: Tocilizumab Monotherapy NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy 11.5%TCZ - All Participants NCT02001987 · Phase 3 · registry result, not featured evidence 11.6%TCZ MONO - All Participants NCT02001987 · Phase 3 · registry result, not featured evidence 18.2% NCT01734993 · Phase 3 · registry result, not featured evidence 5.8% NCT01951170 · Phase 3 · registry result, not featured evidence 6.7% NCT01655381 · Phase 3 · registry result, not featured evidence 6% NCT01988012 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | — | a alanine aminotransferase increased 19.7% aspartate aminotransferase increased 13.6% leukopenia 12.1% NCT01941095 · Phase 3 · combination show 43 more resultsalanine aminotransferase increased 29% aspartate aminotransferase increased 25.8% neutropenia 19.4% NCT01941095 · Phase 3 · monotherapy bronchitis 15.8% cough 12.3% nasopharyngitis 12.3% NCT02031471 · Phase 3 · monotherapy · Rheumatoid Arthritis · phase 3 8 mg/kg upper respiratory tract infection 24.3% (placebo 7.4%) urinary tract infection 16.1% (placebo 5.1%) hypertension 13.4% (placebo 3.1%) NCT00106535 · Phase 3 · combination 4 mg/kg upper respiratory tract infection 9.2% (placebo 7.4%) hypertension 5.7% (placebo 3.1%) urinary tract infection 5.7% (placebo 5.1%) NCT00106535 · Phase 3 · combination alanine aminotransferase increased 22.2% upper respiratory tract infection 20.6% aspartate aminotransferase increased 15.2% NCT01194414 · Phase 3 upper respiratory tract infection 17.7% alanine aminotransferase increased 15.6% nasopharyngitis 14% NCT01194414 · Phase 3 alanine aminotransferase increased 29.8% aspartate aminotransferase increased 21.4% upper respiratory tract infection 19.3% NCT01194414 · Phase 3 upper respiratory tract infection 16.7% alanine aminotransferase increased 14.6% nasopharyngitis 14.6% NCT01194414 · Phase 3 alanine aminotransferase increased 15.3% (placebo 6%) upper respiratory tract infection 11.9% (placebo 6.4%) aspartate aminotransferase increased 9.2% (placebo 4.6%) NCT01232569 · Phase 3 alanine aminotransferase increased 14.3% (placebo 6%) upper respiratory tract infection 12.5% (placebo 6.4%) nasopharyngitis 9.5% (placebo 2.3%) NCT01232569 · Phase 3 nasopharyngitis 7% diarrhoea 3.9% alanine aminotransferase increased 2.3% NCT02573012 · Phase 4 · registry result, not featured evidence · combination nasopharyngitis 9.9% alanine aminotransferase increased 6.9% aspartate aminotransferase increased 6.9% NCT02573012 · Phase 4 · registry result, not featured evidence · combination rheumatoid arthritis flare 38.9% upper respiratory infection 38.9% hypercholesterolemia 31.5% NCT01717859 · Phase 4 · registry result, not featured evidence respiratory tract infection nos 46.2% musculoskeletal pain 30.8% urinary tract infection 26.9% NCT01715831 · Phase 4 · registry result, not featured evidence alanine aminotransferase/aspartate aminotransferase elevations 32.4% leukopenia 22.1% upper respiratory tract infection 17.2% NCT01149057 · Phase 4 · registry result, not featured evidence hypertransaminasaemia 15.6% hypercholesterolaemia 9.4% leukopenia 7.3% NCT01399697 · Phase 4 · registry result, not featured evidence · combination hypertransaminasaemia 9.6% aphthous stomatitis 0% hypercholesterolaemia 0% NCT01399697 · Phase 4 · registry result, not featured evidence · combination hypertransaminasaemia 14.5% aphthous stomatitis 3.6% urinary tract infection 3.6% NCT01399697 · Phase 4 · registry result, not featured evidence · combination hypertransaminasaemia 4.9% aphthous stomatitis 0% hypercholesterolaemia 0% NCT01399697 · Phase 4 · registry result, not featured evidence hypertransaminasaemia 12.2% aphthous stomatitis 7.3% hypercholesterolaemia 7.3% NCT01399697 · Phase 4 · registry result, not featured evidence sinusitis 8.3% headache 6.7% nausea 6.7% NCT01163747 · Phase 4 · registry result, not featured evidence · combination 8 mg/kg rheumatoid arthritis 47.6% lower respiratory tract infection 42.9% nasopharyngitis 38.1% NCT01195272 · Phase 4 · registry result, not featured evidence 8 mg/kg upper respiratory tract infection 11.1% nasopharyngitis 10.5% hypertension 8% NCT01119859 · Phase 4 · registry result, not featured evidence investigations 30.5% blood and lymphatic system disorders 7.4% infections and infestations 7.4% NCT01089023 · Phase 4 · registry result, not featured evidence 8 mg/kg urinary tract infection 11.4% (placebo 10%) hypercholesterolemia 8.6% (placebo 10%) elevated alt 5.7% (placebo 0%) NCT01034397 · Phase 4 · registry result, not featured evidence alanine aminotransferase increased 4.5% transaminases increased 4% respiratory tract infection 3% NCT00996203 · Phase 4 · registry result, not featured evidence drowsiness 8.7% NCT02010216 · Phase 4 · registry result, not featured evidence 8 mg/kg acute bronchitis 9.4% leucopenia+lymphopenia 9.4% hepatopathy 6.3% NCT01010503 · Phase 4 · registry result, not featured evidence nasopharyngitis 15% hypertension 12.8% nausea 8.3% NCT02046616 · Phase 3 · registry result, not featured evidence · combination lower respiratory tract infection 28.6% nasopharyngitis 23.8% urinary tract infection 23.8% NCT02046603 · Phase 3 · registry result, not featured evidence · monotherapy nasopharyngitis 23.6% diarrhoea 22.9% alanine aminotransferase increased 22.1% NCT02046603 · Phase 3 · registry result, not featured evidence · combination influenza 10.1% cough 7% bronchitis 6.6% NCT01941940 · Phase 3 · registry result, not featured evidence nasopharyngitis 23.3% fatigue 12% nausea 12% NCT01987479 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 42.9% dyslipidaemia 23.8% upper respiratory tract infection 19% NCT01668966 · Phase 3 · registry result, not featured evidence transaminases increased 11.3% upper respiratory tract infection 7% urinary tract infection 7% NCT01995201 · Phase 3 · registry result, not featured evidence · combination injection site erythema 8.1% urinary tract infection 8.1% back pain 5.4% NCT01995201 · Phase 3 · registry result, not featured evidence · monotherapy rheumatoid arthritis 13.7% bronchitis 11.5% rhinitis 9.4% NCT02001987 · Phase 3 · registry result, not featured evidence rheumatoid arthritis 18.6% bronchitis 16.3% ear infection 11.6% NCT02001987 · Phase 3 · registry result, not featured evidence bronchitis 45.5% arthralgia 36.4% urinary tract infection 27.3% NCT01734993 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 28.8% rheumatoid arthritis 21.2% neutropenia 11.5% NCT01951170 · Phase 3 · registry result, not featured evidence bronchitis 40% back pain 33.3% asthenia 26.7% NCT01655381 · Phase 3 · registry result, not featured evidence neutropenia 12% hepatic enzyme increased 11% leukopenia 11% NCT01988012 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 49 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
tocilizumab
show 53 more results
show 74 more results
show 50 more results
show 84 more results
show 13 more results
show 13 more results
show 37 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
+ 596 further endpoints in the CSV export.
COVID-19
Shared mechanism: IL-6 receptor · full COVID-19 pipeline
BAT1806 · Tofidence
Marketed by Organon and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
tocilizumab · Actemra / RoActemra
Marketed by Roche and partners
NCT04381936 · Phase 3 · recruiting
Patients were randomly assigned to tocilizumab or usual care alone, but there was no placebo and neither patients nor doctors were blinded. The primary endpoint, death from any cause within 28 days, is objective and was significantly lower with tocilizumab in 4116 patients (rate ratio 0.85, p=0.0028).
Next expected readout: December 2026 · NCT04363853 (registry estimate)
Reported efficacy
Time to Hospital Discharge or "Ready for Discharge" up to Day 28: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) (missed)
Result source: NCT04409262
Results for COVID-19
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
BAT1806: no structured comparison results are available for COVID-19.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT1806's landscape · tocilizumab's landscape